General AML

American Society of Clinical Oncology Abstract Deadline Approaches

The American Society of Clinical Oncology (ASCO) will hold its 2017 annual meeting on June 2nd–6th at McCormick Place in Chicago, Illinois. The…

Cynthia Umukoro , Jan 17, 2017

General AML

Acute Graft Versus Host Disease increases due to chemotherapy induced immune stimulation in AML patients

Acute Graft versus Host Disease (aGvHD) is a chief cause of mortality and comorbidities post-transplantation. This condition can also limit the…

Cynthia Umukoro , Jan 17, 2017

General AML

All-Trans Retinoic Acid in the treatment of APL

As part of their 70th year anniversary, Blood are currently featuring flashbacks of key papers from their history, accompanied by new editorials. One…

Cynthia Umukoro , Jan 13, 2017

General AML

Prof. Gail Roboz | ASH 2016 | New classification of AML

Cynthia Umukoro , Jan 12, 2017

General AML

Androgen therapy improves survival in older AML patients

Elderly patients with Acute Myeloid Leukemia (AML) have a poor prognosis and investigations into new maintenance therapies could improve the outcomes…

Cynthia Umukoro , Jan 10, 2017

General AML

FDA Halts Phase I Trials of Vadastuximab Talirine in AML

Clinical trials of the experimental drug vadastuximab talirine (SGN-CD33A; a CD33-directed antibody drug conjugate) for patients with Acute Myeloid…

Cynthia Umukoro , Jan 10, 2017

General AML

EHA 22nd Congress Abstract Submissions Open

Cynthia Umukoro Stephanie Hill , Jan 4, 2017

General AML

Can azacitidine be used as a pre-HSCT treatment in pediatric patients with advanced MDS?

Advanced Myelodysplastic Syndrome (MDS) in pediatric patients with an increased leukemia blast count in the Bone Marrow (BM) and/or in the peripheral…

Cynthia Umukoro , Jan 4, 2017

General AML

Prof. Norbert Vey | ASH 2016 | Anti CD33 agents in AML

Cynthia Umukoro , Dec 19, 2016

General AML,   FLT3

ASH 2016: FLT3 inhibitors - An overview of midostaurin

Cynthia Umukoro , Dec 19, 2016